He Zhang

Dr. He Zhang


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 December 2024 in International Immunopharmacology
Verified
Journal Article
Closed access
ZCZiwei Cai
Ziwei Cai
CLCongmin Liang
Congmin Liang
KHKailun Huang
Kailun Huang
JLJiankun Luo
Jiankun Luo
RLRenjian Lu
Renjian Lu
JCJialong Chen
Jialong Chen

8 February 2023 in Ecotoxicology and Environmental Safety
Verified
Journal Article
Open access
HZHe Zhang
He Zhang
ZXZhefan Xie
Zhefan Xie
YPYongming Peng
Yongming Peng
AXAilun Xie
Ailun Xie
CFChunlai Fu
Chunlai Fu
JCJialong Chen
Jialong Chen
Rotenone, a widely used pesticide, causes dopaminergic neurons loss and increase the risk of Parkinson's disease (PD). However, few studies link the role of PARP1 to neuroinflammatory response and autophagy dysfunction in rotenone-induced neurodegeneration. Here, we identified that PARP1 overactivation caused by rotenone led to autophagy dysfunction and NLRP3-mediated inflammation. Further results showed that PARP1 inhibition could reduce NLRP3-mediated inflammation, which was effectively eliminated by TFEB knockdown. Moreover, PARP1 poly(ADP-ribosyl)ated TFEB that reduced autophagy. Of note, PARP1 inhibition could rescue rotenone-induced dopaminergic neurons loss. Overall, our study revealed that PARP1 blocks autophagy through poly (ADP-ribosyl)ating TFEB and inhibited NLRP3 degradation, which suggests that intervention of PARP1-TFEB-NLRP3 signaling can be a new treatment strategy for rotenone-induced neurodegeneration.

28 August 2025 in PeerJ
Verified
Journal Article
Open access
PDF file
JLJiankun Luo
Jiankun Luo
JSJiyuan Shu
Jiyuan Shu
WPWeiqing Pan
Weiqing Pan
DGDuanqin Guan
Duanqin Guan
CLCongmin Liang
Congmin Liang
HZHe Zhang
He Zhang
Background: Peer support is increasingly recognized as a valuable method for managing blood glucose levels and reducing the risk of chronic complications in patients with diabetes. This systematic review and meta-analysis specifically evaluated the effect of peer support on HbA1c levels in middle-aged and elderly patients with type 2 diabetes and explored the potential benefits of peer interactions on glycemic control. Methodology: A comprehensive search was conducted across six databases from January 2018 to July 2023, with a focus on randomized controlled trials (RCTs) that compared peer support interventions to standard diabetic care in adults. Among the 3,395 articles identified, eleven studies involving 2,187 participants were included. The quality of each study was assessed using the Cochrane risk of bias tool. A random-effects model was employed to calculate the mean difference (MD) in HbA1c changes, with additional subgroup analyses for specific contexts. Results: The findings revealed a modest but statistically significant improvement in HbA1c levels in groups receiving peer support (MD: −0.20; 95% CI [−0.37 to −0.02]; p = 0.03). More pronounced benefits were observed in interventions conducted within formal medical settings, those involving high-frequency contact, and those in group sessions, particularly among elderly patients. Conclusions: The results suggest that while peer support provides a slight improvement in HbA1c levels, other intervention strategies—such as frequent contact, group sessions, and formal medical settings—may offer greater glycemic control benefits in elderly patients with type 2 diabetes. These findings support incorporating peer support into diabetes care and underscore the need for further research with larger samples and standardized protocols.